FIGURE 2.

A diagram of the pharmacodynamic model of inebilizumab in adults. B₀, pro‐B cell; B_i, CD20⁺ B cells in each aging compartment; C, serum concentration of inebilizumab; CL, clearance; IV, intravenous; k_CD19, rate constant representing the maturation of pro‐B to CD20⁺ B cells in the circulation; k_dec, first‐order rate constant describing the decrease of V_max over time; k_inebi, accelerated removal of CD19⁺ pro‐B and mature B cells by inebilizumab; K_M, concentration to achieve the half of V_max; V_c, volume of distribution in the central compartment; n, number of transit compartments; Q, intercompartmental clearance; V_p, volume of distribution in the peripheral compartment; V_max, maximum velocity of Michaelis–Menten equation; Λ, longevity (lifespan) of blood CD20⁺ B cells; k_t, transit rate constant defined as the ratio of n and Λ